NASDAQ$KYMR
Kymera Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
KYMR Q2 2024 — $1.2M revenue, 30.00 EPS
In addition, the results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the resu. Kymera Therapeutics Inc reported Q2 2024 results. Diluted EPS came in at $30.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $1.2M.
- Diluted EPS: $30.00.
- Operating income: $51K.
Headline financials
Revenue & EPS history
Kymera Therapeutics · Revenue · Quarterly
$25.7M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.0%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.3%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+23.5%
Q3 2023
Best reaction
-32.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | +1.5% | -0.2% | |
| Q4 2025 | +4.8% | -4.8% | -13.8% | |
| Q3 2025 | +0.3% | -1.8% | +10.9% | |
| Q1 2025 | -2.0% | -3.3% | +54.8% | |
| Q4 2024 | -14.5% | -13.2% | -16.2% | |
| Q3 2024 | -2.5% | +0.0% | -1.7% | |
| Q2 2024 | +1.4% | +2.6% | +9.6% | |
| Q1 2024 | +3.2% | +6.1% | -11.4% | |
| Q4 2023 | +8.2% | +12.7% | +5.3% | |
| Q3 2023 | +23.5% | +41.6% | +79.8% | |
| Q2 2023 | +5.0% | -7.4% | -7.6% | |
| Q1 2023 | -6.1% | -10.3% | -12.5% | |
| Q4 2022 | -0.2% | -0.5% | -7.0% | |
| Q3 2022 | +7.3% | +5.5% | +7.1% | |
| Q2 2022 | +8.3% | +7.4% | -8.5% | |
| Q1 2022 | -32.7% | -41.8% | -55.3% | |
| Q4 2021 | +11.4% | +7.1% | +12.4% | |
| Q3 2021 | -3.6% | -6.5% | -19.1% | |
| Q2 2021 | -3.3% | -8.9% | -3.6% | |
| Q1 2021 | +6.8% | +9.1% | +15.7% | |
| Q4 2020 | -2.2% | +2.3% | -41.7% | |
| Q3 2020 | +8.7% | +14.6% | +32.2% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro